All News

Found 794,409 articles

• Phio Pharmaceuticals Announces Exercise of Warrants for $2.8 Million Gross Proceeds

  12/7/2023

  Phio Pharmaceuticals Corp. today announced the agreement by several accredited investors to exercise certain outstanding warrants to purchase up to an aggregate of 2,130,252 shares of common stock of the Company originally issued in October 2018 through June 2023.

• Korro Announces Selection of its First Development Candidate for the Potential Treatment of Alpha-1 Antitrypsin Deficiency (AATD)

  12/7/2023

  Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a biopharmaceutical company focused on developing a new class of genetic medicines for both rare and highly prevalent diseases, has nominated its first development candidate, KRRO-110, for the potential treatment of AATD.

• Vittoria Biotherapeutics Announces FDA Clearance of IND Application for VIPER-101 to Treat T-Cell Lymphoma

  12/7/2023

  Vittoria Biotherapeutics has announced the clearance of an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for the initiation of a first-in-human Phase 1 clinical trial to evaluate the Company’s lead candidate, VIPER-101, a gene-edited, autologous, CAR-T cell therapy for treatment of patients with relapsed or refractory T-cell lymphoma.

• Providence Medical Technology Announces New Publication Demonstrating High Fusion Rates and Successful Outcomes in Previously Failed Cervical Fusion Patients

  12/7/2023

  Providence Medical Technology, Inc., a medical device innovator focused on improving surgical outcomes for high-risk spine surgery patients, announced a new publication in the Journal of Clinical Neuroscience.

• Hepion Pharmaceuticals Announces Restructuring Plan to Enhance Shareholder Value and Management Changes

  12/7/2023

  Hepion Pharmaceuticals, Inc. today announced that its Board of Directors has approved a strategic restructuring plan with the objective of preserving capital by initially reducing operating costs by approximately 60% going forward.

• AudioCure Pharma Receives Hearing Technology Innovator Award for its Innovative Compound AC102 for the Treatment of Sudden Hearing Loss

  12/7/2023

  AudioCure Pharma GmbH announced that it has been awarded for its innovative compound AC102 by the Hearing Technology Innovator Awards™, honoring technological innovation and breakthroughs in the hearing industry.

• BrainStorm Cell Therapeutics Announces Outcome of FDA Meeting on NurOwn® in ALS

  12/7/2023

  BrainStorm Cell Therapeutics Inc. today announced the completion of a productive meeting with the U.S. Food and Drug Administration (FDA) to discuss NurOwn®, its investigational treatment for amyotrophic lateral sclerosis (ALS).

• Rentschler Biopharma SE appoints Gunnar Voss von Dahlen as Chief Financial Officer and completes Executive Board

  12/7/2023

  Rentschler Biopharma SE, a leading contract development and manufacturing organization for biopharmaceuticals, including Advanced Therapy Medicinal Products, announced that Gunnar Voss von Dahlen has been appointed as Chief Financial Officer, effective December 1, 2023.

• SpyBiotech Announces First Patient Dosed in Phase I Trial of SPYVLP01

  12/7/2023

  SpyBiotech announced that the first subject has been dosed with SPYVLP01, a candidate vaccine targeting human cytomegalovirus using its Hepatitis B virus-like-particle platform technology.

• Secura Bio Announces the Addition of Two New Board of Directors Members

  12/7/2023

  Secura Bio, Inc. today announces that it has added two members to the board of directors of Secura Bio Holdings, Inc.

• AlzeCure Presents at Redeye Investor Forum in Göteborg on December 14

  12/7/2023

  AlzeCure Pharma AB announced that the company is participating at Redeye Investor Forum in Göteborg on December 14 at 18:50 CET, where CEO Martin Jönsson will present and answer questions about the latest developments and the company's plans going forward.

• Regeneron to Share Progress of Novel Combination Therapies in Oncology at ESMO IO

  12/7/2023

  Regeneron Pharmaceuticals, Inc. announced the presentation of new and updated data on multiple combination therapies from its oncology pipeline at the European Society for Medical Oncology Immuno-Oncology Congress 2023 from December 6 to 8 in Geneva, Switzerland.

• Justera Announces 2023 AGM Results

  12/7/2023

  Justera Health Ltd. (CSE: VTAL) (OTC Pink: SCRSF) ("Justera" or the "Company") announces the voting results from the Annual General and Special Meeting of Shareholders (the "Meeting") which was held on December 6, 2023.

• Lexaria's Investigational New Drug Application Filing Update

  12/7/2023

  Lexaria Bioscience Corp. announces that the Company's anticipated submission of an Investigational New Drug application with the U.S. Food and Drug Administration for its planned U.S. Phase 1b Hypertension Clinical Trial is expected to be filed within approximately 45 days.

• Faron Announces Publication of Full Analysis from Phase 1/2 MATINS Trial of Bexmarilimab in Solid Tumors in Cell Reports Medicine

  12/7/2023

  Faron Pharmaceuticals Ltd. announces the publication of the full safety and anti-tumor efficacy results from the first-in-human Phase 1/2 MATINS trial of bexmarilimab in patients with treatment-refractory late-stage solid tumors in Cell Reports Medicine.

• Pillar Biosciences to Present at NYBIO | NYSE Life Science Company Showcase on December 14th

  12/7/2023

  Pillar Biosciences is pleased to announce that Randy Pritchard , Chief Executive Officer, and Vincent Ricci , Chief Financial Officer, will be presenting at the NYBIO | NYSE Life Science Company Showcase on December 14th.

• Mission Bio Announces Over 20 Presentations Demonstrating the Utility of Tapestri Across AML, Multiple Myeloma, and Lymphoma at the 2023 ASH Annual Meeting

  12/7/2023

  Mission Bio , a leader in single-cell multiomic solutions for precision medicine, announced today new data generated by clinical researchers from leading biopharma companies and top academic institutions will be showcased at the 65th ASH Annual Meeting and Exposition.

• Remix Therapeutics to Present Preclinical Data Demonstrating MYB mRNA Degradation in AML at the 65th American Society of Hematology Annual Meeting and Exposition (ASH)

  12/7/2023

  Remix Therapeutics today announced an upcoming presentation introducing REM-422, the Company's potent, selective, oral small molecule messenger RNA (mRNA) degrader, as a potential treatment for MYB-driven cancers.

• Synlogic Announces Abstract Accepted for Poster Presentation at the International Conference on Microbiome Engineering 2023

  12/7/2023

  Synlogic, Inc. announced that an abstract outlining the SYNB1353 program as a potential treatment for homocystinuria (HCU) has been accepted and will be presented at the International Conference on Microbiome Engineering 2023, held in Berkeley, California on December 8th to 10th.

• FORE Biotherapeutics to Present at the 2023 RBC Capital Markets Private Company Conference

  12/7/2023

  FORE Biotherapeutics today announced that the Company will be presenting at the 2023 RBC Capital Markets Private Company Conference.